Is Mutation Testing Worth It — If You Can't Afford the Drug?

Testing costs vary significantly by the panel being used. A single-gene test costs considerably less than a comprehensive next-generation sequencing panel, and for many cancer types a focused panel identifies the most clinically important mutations. Ask your oncologist whether a smaller panel would answer the key question before committing to the most extensive option. Some government hospitals and ICMR-affiliated cancer centres offer subsidised genomic testing under national cancer programmes — if you are registered at a government facility, ask whether you qualify before paying privately. Your oncologist can also confirm whether tissue stored from your existing biopsy can be used, which removes the cost of a new procedure entirely.

A positive result gives you a position, not a dead end. Clinical trials are the most direct route to a drug without its list price — many actively seek patients with confirmed mutations and provide the drug throughout the study period. Patient assistance programs are worth checking: manufacturers of drugs registered with CDSCO often run formal access schemes, and your oncologist can initiate the application on your behalf. Generic and biosimilar versions of some targeted drugs are available in India at substantially lower prices than the originator, and your oncologist can confirm which ones are clinically equivalent for your cancer type and stage. None of these conversations can begin without a confirmed result.

Distance is a real barrier and not every trial will be practical. Ask your oncologist to check whether a nearby CION centre is recruiting for any relevant study, and what the visit schedule looks like — some trials require frequent visits early but only monthly check-ins once the dosing phase stabilises. If travel is genuinely not possible, ask whether the same drug is available through a patient assistance program or generic route instead. The point of asking about trials is to understand your full range of options, not to commit to one that does not fit your circumstances.

A result with no actionable finding still has clinical value. It tells your oncologist which chemotherapy combination to use with confidence rather than by exclusion. For several cancers — including certain lung, colorectal, and gastric types — knowing which mutations are absent shapes the choice between regimens that look similar on paper but perform differently in practice. NCCN guidance for several of these cancer types recommends testing before first treatment specifically because the standard regimen may differ depending on the molecular profile, even when no targeted drug is being considered.

For mutations with a hereditary component — BRCA1, BRCA2, Lynch syndrome variants, and others — your result directly concerns your close family members. A confirmed finding means your children, siblings, and parents can consider their own testing at far lower cost than a full cancer diagnostic workup. Preventive and monitoring options exist for people who carry these mutations without yet having cancer, and those options are most useful when identified early. Your oncologist or a genetic counsellor can explain which findings in your result, if any, carry a hereditary implication and what the testing pathway looks like for family members.

That is a conversation worth having directly. Ask whether any clinical trials for your cancer type require biomarker status as an entry criterion — if they do, the test becomes necessary even if it would not change your immediate treatment. Also ask whether NCCN, ASCO, or ESMO guidance for your specific cancer type and stage recommends testing; guidelines are updated regularly, and a recommendation that did not exist two years ago may apply now. If you remain uncertain after that conversation, asking for a second opinion from another oncologist is a reasonable step, and one that most oncology teams will support.